目的:观察吉西他滨联合奈达铂治疗晚期非小细胞肺癌(NSCLC)的疗效及不良反应.方法:对确诊为晚期NSCLC的24例患者采用吉西他滨和奈达铂的联合化疗方案,第1日和第8日静脉滴注吉西他滨1 000 mg/m2,30 min内静脉滴注完,化疗第1日静脉滴注奈达铂80 mg/m2,21 d为一疗程,共治疗6个疗程.结果:24例患者中部分缓解10例,疾病稳定6例,疾病进展8例,有效率为41.7%(10/24),疾病控制率为66.7%(16/24).中位疾病进展时间(TTP)为3.2个月,中位生存期为7.9个月.主要的不良反应为骨髓抑制,部分患者有外周神经毒性和恶心、呕吐症状,但症状均较轻.结论:吉西他滨联合奈达铂治疗晚期NSCLC近期疗效较好,患者普遍可以耐受其不良反应.%Objective:To observe the efficacy and the side -effects of gemcitabine ( GEM) combined with nedaplatin (NDP) on advanced non-small cell lung cancer (NSCLC). Methods; 24 patients with NSCLC were treated with gemcitabine (GEM 1 000 mg/m2, ivdrip, d1, d8) plus nedaplatin (NDP 100 mg/m2, ivdrip, d1, every 3 weeks) , each 6 cycles. Results: 10 patients out of 24 were partial response , 6 patients were stable , 8 patients were progressive. The RR was 41. 7% (10/24). Disease control rate was 66. 7%. The median time to progress was 3. 2 months and the median survivaltime was 7. 9 months. The main side-effects were fairly, including myelosuppression , partial peripheral neurotoxicity , nausea and vomitin. Conclusion: Gemcitabine combined with nedaplatin is effective and well tolerated in patients with advanced non -small cell lung cancer.
展开▼
